Connect Biopharma Holdings Ltd Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Huang James, was filed 02 Jun 2026.
Connect Biopharma Holdings Ltd: what insiders have been doing
Every trade that managers of Connect Biopharma Holdings Ltd disclose to SEC (Form 4) is tracked on this page. From 9 November 2025 to 9 November 2026, the disclosure feed for Connect Biopharma Holdings Ltd logged 8 filings by 3 insiders.
No insider sold shares on the market over the period. Instead, the filings list 2 purchases totalling €3.8M, made by 1 insider. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 1 senior executive among the declarants. The largest single trade was a purchase of €3.5M by Huang James, published on 1 April 2026.
Compared with its exchange (5,808 companies, median 19 filings), a count of 8 filings is below the norm. Our records for Connect Biopharma Holdings Ltd go back to 2026, with 2 purchases and no sales on the open market in total. The 10-K for the year ended 31 December 2025 shows 64,000 USD of revenue and -55.5 m USD of net income.
The most recent open-market purchase was published on 2 June 2026, 159 days ago. Typically, a trade is published a median of 1 day after it takes place. For comparison, the SEC allows two business days to file a Form 4.
Other companies in the same market with recent insider buying flagged by our signals: GameStop Corp. and Heico Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleSince the insiders bought
- +0.0%Entry US$0.00 · Close at T+90 US$0.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Connect Biopharma Holdings Ltd Strong Buy (bullish), based on 8 analysts. Average price target: US$5.88.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 5,000 shares0Ordinary SharesSEC:0002115875-26-000007:0
- 8,984 shares0Ordinary SharesSEC:0001835268-26-000039:0
- 6,718 sharesOrdinary SharesSEC:0001835268-26-000021:0
- 3,738 sharesOrdinary SharesSEC:0001835268-26-000022:0
- 150,000 shares@ US$2.4774100.0% of flowOrdinary SharesSEC:0001193125-26-253607:0Canonical exit: 27 Aug 2026 (T+90)
- 2,816 shares0Ordinary SharesSEC:0002115875-26-000004:0
- 5,061 shares0Ordinary SharesSEC:0001241357-26-000004:0
- 1,160,000 shares@ €2.980891.5% of flowOrdinary SharesSEC:0001193125-26-138012:0Canonical exit: 29 Jun 2026 (T+90)
8 of 8 declarations
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Ltd is a biopharmaceutical company focused on developing treatments for immunological diseases. It is listed on NASDAQ under the symbol CNCT.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
